Generic Name and Formulations:
Gatifloxacin 0.3%; oph soln; contains benzalkonium chloride.
Indications for ZYMAR:
Susceptible bacterial conjunctivitis.
Adults and Children:
1 drop every 2hrs while awake (max 8 times/day) on days 1 and 2, then 1 drop up to 4 times/day while awake on days 3–7.
Risk of corneal endothelial cell injury: do not administer into anterior chamber of the eye. Discontinue if superinfection or hypersensitivity occurs. Remove contact lenses. Pregnancy. Nursing mothers.
Conjunctival irritation, increased lacrimation, keratitis, papillary conjunctivitis, chemosis, conjunctival hemorrhage, dry or red eye, eye discharge or pain, eyelid edema, headache, reduced visual acuity, taste disturbance.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC